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Age Primary Adjuvant RT region 
No of 
positive 
nodes 
ECE Site of recurrence 
Time to 
recurrence 
post RT 
Mortality 
post 
recurrence 
64 Neck Neck 6/61 No - - - 
57 Unknown Neck 1/29 Yes - - - 
81 Cheek Neck 2/31 Yes Distant 4 months RIP at 4 months 
43 Leg Groin 9/25 No - - - 
41 Back Axilla 3/16 No - - - 
19 Neck Neck 1/35 Yes Distant 1 month Alive at 25months 
79 Eyelid Neck 1/58 Yes Local + Distant 3.5 months 
Alive at  
22months 
69 Auricular Neck 4/50 Yes - - - 
68 Unknown Neck 1/64 Yes - - - 
65 Cheek Neck 1/24 No - - - 
75 Unknown Neck 4/45 Yes Distant 4 months RIP at 1 month 
73 Neck Neck 0 No - - - 
62 Leg Groin 5/10 No - - - 
70 Leg Groin 13/33 No - - - 
57 Foot Groin 3/8 Yes Local + Distant 
0 months + 
2.8 months 
RIP at 
10months 
80 Cheek Neck 38/42 Yes Distant 1 month RIP at 7months 
48 Unknown Axilla 13/33 Yes - - - 
57 Hand Axilla 13/33 Yes Distant 2 months Alive at 8months 
63 Leg Groin 2/25 Yes - - - 
37 Leg Groin 1/9 Yes - - - 
 
Conclusion: Radiotherapy was well tolerated and effective as 
no patient developed lymph node field relapse. However 
patients are at risk of early local and distant relapse, 
especially those with extranodal extension. Consideration 
should be given to the use of routine PET CT for high risk 
patients.  
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Purpose or Objective: Surgery is the cornerstone in the 
management of sarcomas. The aim of this study was to 
evaluate intensity-modulated radiotherapy (RT) with 
tomotherapy followed by surgery in terms of acute gastro-
intestinal (GI) toxicities, especially regarding the high-level 
of prescribed dose (54 Gy/30 fractions/6weeks). 
 
Material and Methods: From April 2009 to September 2013, 
48 patients were included in a prospective multicenter study. 
Feasibility of tomotherapy, acute toxicities and local control 
at 3 years were the principal and secondary objectives. 
Inclusion criteria were operable, biopsy-proven, 
retroperitoneal liposarcoma. Patients with non-operable 
tumors validated after multi-disciplinary team evaluation, 
other histology or metastatic disease were excluded.Clinical 
Target Volume (CTV) and mains organs at risk (contralateral 
kidney, duodenum, bowel bag) were systematically 
delineated with the surgeon. Dose constraints to the bowel 
bag were defined as V45 Gy<33% and V30 Gy<50%. Surgery 
was planned 4 to 8 weeks after RT. Clinical visits were 
performed weekly during RT, before surgery, and 2 and 6 
months after surgery. Toxicity was recorded according to 
CTCAE V4.0 scale. 
 
Results: For acute GI toxicity, 46/48 patients were 
evaluable. All patients completed the radio surgical schedule 
without dose reduction. Mean age was 62 years (36-82). All 
patients were OMS≤2 except one (OMS=3). Mean CTV was 
2954 cc (920-4989. Mean small bowel and duodenal volumes 
were 2725 (1355-4090) and 73 cc (33-113), respectively. 
Monobloc exerese was systematically achieved and all 
patients underwent homolateral nephrectomy. Twenty-nine 
patients underwent bowel resection, including large bowel 
(28/29), small bowel(4/29) and duodenum (1/29). Mean 
weight loss during RT was 5,4 kg (about 8% of mean body 
weight) and 8,9 kg at the first visit after surgery. At 2 
months, grade 3 toxicities included duodenal stenosis (1/46), 
intestinal fistula (1/46) and enterocolitis (1/46) and grade 4 
toxicity included GI fistula (1/46). At 6 months, no GI 
toxicities were observed. Three patients died within 6 
months after surgery, 2 of which were related to treatment: 
one respiratory disorder 6 days after surgery and 1 duodenal 
perforation with necrosis and infection 4 months after 
surgery. 
 
Conclusion: For patients with retroperitoneal liposarcoma, 
preoperative 54 Gy RT appears feasible. Due to the low rate 
of severe complications, no statistic correlations with dose in 
digestive structure were performed. 
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Purpose or Objective: The standard treatment of high grade 
soft tissue sarcoma (STS) is surgery followed by adjuvant 
radiotherapy (RT); chemotherapy (CT) can be an option in 
selected patients due to reported benefit in terms of disease 
free survival. The association of RT with CT might increase 
tissue reactions with the consequent risk of unplanned 
treatment interruptions resulting in an increased risk of 
treatment failure. This retrospective study analyze the safety 
and feasibility, respectively in terms of additional toxicity 
and compliance, of concurrent chemoradiotherapy (CTRT) in 
adjuvant treatment of STS.  
 
Material and Methods: Data of 84 STS patients treated with 
surgery and adjuvant RT from June 1994 to November 2014 at 
the University of Florence, were retrospectively collected. 
Anthracycline-based CT was performed in high risk patients. 
Acute and late local toxicity of RT treatment were assessed 
respectively by Common Terminology Criteria for Adverse 
Events (CTCAE) 4.0 and RTOG/EORTC criteria for the Late 
Radiation Toxicity. CT-related hematological Toxicity was 
assessed by CTCAE 4.0. 
 
Results: Twenty-four (28.6%) patients received CTRT. Mean 
follow-up was 5.6 years (range 0.4-18.8). At the time of our 
analysis 8 (9,5%) patients had a local relapse, 17 (19.8%) 
developed distant metastases, and 14 (16.7%) died of 
metastatic disease. Local Recurrence Free Survival (LRFS), 
Distant Relapse Free Survival (DRFS) and Overall Survival (OS) 
were respectively 83.4%, 70% and 69.5%. Grade ≥3 leucopenia 
occurred in 6 CTRT patients, resulting in early interruption of 
the CT treatment in 3 cases. Skin acute toxicity was 
developed in 59 (70,2%) of patients ; G3 skin toxicity 
occurred in 19 (22.6%) cases and determined treatment 
interruption in 15 (17.9%) patients with a mean treatment 
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delay of 10 days (range 4-20 days). No wounds complication 
occurred. Grade 1-2 fibrosis, joint stiffness and limb edema 
occurred in respectively 27 (32.1%), 9 (10.7%) and 18 (21.4%) 
patients. Age > 60 years was the only predictor of LR at 
multivariate analysis (HR: 5.26; 95% CI: 1.11-25.05; p=0.037) 
and correlated with impaired DRFS (86.1% vs 39.9%; p=0.006). 
No statistical significant parameters influencing OS. No 
correlation was found between CTRT and acute local toxicity 
(p= 0.75), and in any case the association determined a 
definitive interruption of the treatment. There was no 
difference in acute (p=0.25) and late toxicity (p=0.78) 
incidence in the IMRT and 3DCRT group. 
 
Conclusion: Concurrent CTRT is a well tolerated treatment 
option with no additional toxicity compared to exclusive RT 
or sequential CTRT, resulting in adequate compliance to 
treatment. Combined postoperative CTRT could reduce the 
gap between surgery and RT in high risk patients eligible for 
CT. Further studies are needed to assess the optimal timing 
and sequence of adjuvant therapies. 
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Purpose or Objective: Myxofibrosarcomas are a historically 
heterogeneous group of tumors that exhibit a propensity for 
local recurrence. The objectives of this study were to analyze 
the prognostic factors and outcomes of patients with MFS 
treated. 
 
Material and Methods: We retrospectively reviewed the 
records of 41 patients with pathologically confirmed MFS, 
who underwent surgery and radiotherapy from November 
1995 to June 2014. Clinicopathologic features, treatments, 
and patient outcomes were reviewed. 
 
Results: Fourty one patients were identified, of whom 19 
were men (46 %) and 22 were female (54%). The median age 
was 66 years (35-89). Mean follow-up was 3.9 years (0.3-
13.9). Stage I and II disease was present respectively in 21 
(51.2%) and 20 (48.8%) patients. Most patients (73%) had a 
high histological grade disease. Primary tumor was located at 
the extremities in 36 cases (88%) and at the trunk in 5 (12%); 
21/41 (51%) were superficial lesions. Surgery was performed 
in our center on 33 (80%) patients while 8 (20%) patients 
underwent reoperation after prior surgery in an non-referring 
center; 31 (75%) had a radical surgery while 10 (25%) had a 
marginal resection. Four patients received Anthracycline-
based adjuvant chemotherapy. 
Radiotherapy was delivered to all 41 patients, as pre-
operative treatment in 3 cases (7%, median dose: 50Gy) and 
as adjuvant treatment in 38 patients (93%, median dose 
60Gy). Twenty-two patients underwent radiotherapy within 
90 days since surgery. At a median follow-up of 3.9 years, 
there were 8 (20%) local recurrence (LR), 11 (27%) distant 
metastatic (DM) relapse and 10 (25%) deaths. A significant 
difference on Local recurrence - Free survival (DFS-LR) 
emerged in favour of post-operative radiotherapy compared 
to neoadjuvant radiotherapy (0% vs 72.8%, p=0.0001). 
Multivariate analysis confirmed pre-operative radiotherapy as 
a major predictor of LR (HR=18.6; 95% CI 3.7-93.7; p=0.0001). 
Tumor site was correlated with distant metastasis free-
survival (DFS-DM), showing higher incidence of metastatic 
recurrence for deep lesion compared to superficial lesion 
(72.1% vs 32.4 % p=0.034), as confirmed by Cox univariate 
analysis (HR 3.8; 95% IC 1.01-14.36; p=0.049). LR occurrence 
was the only predictor of impaired overall survival, as 
confirmed by Cox regression univariate analysis (HR 4.44; 95% 
CI 1.28-15.45; p=0.019). 
 
Conclusion: In our series adjuvant radiotherapy yielded 
superior local control compared to neoadjuvant irradiation. 
Deep localization was correlated with an increased risk to 
develop distant metastasis; local recurrence was a major 
predictor of OS. Improvement in local treatment is required 
to increase local control of disease in order to prevent both 
recurrence and metastatic dissemination. 
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Purpose or Objective: To report our long-term results with 
surgery, IOERT and EBRT in recurrent soft-tissue sarcomas of 
the extremities. 
 
Material and Methods: We performed a retrospective 
analysis of 41 patients suffering from recurrent soft-tissue 
sarcoma of the extremities, who received IOERT, surgery and 
EBRT at our institution after prior resection without 
additional radiation. 11 patients (27%) had more than one 
prior resection. Median age was 60 years (28-89) and 49% 
were male. Median tumor size at recurrence was 5 cm and 
69% of the tumors were located in the lower limb. Stage in 
recurrent situation (UICC 7th) was as follows: Ia:2%, Ib:7%, 
IIa:39%, IIb:10%, III:32%, IV:10%. The majority of patients 
showed high grade lesions (FNCLCC G1:10%, G2:20%, G3:71%), 
predominantly liposarcomas (32%) and MFH (29%). Gross total 
resection was achieved in all patients with free margins in 
51% and microscopically positive margins in 49%. IOERT was 
applied to the tumor bed with a median dose of 15 Gy, using 
electron energies of 6-8 MeV and a median cone size of 8 cm. 
IOERT was preceeded (10%) or followed (90%) by EBRT with a 
median dose of 45 Gy. 20% of the patients also received pre- 
and/or postoperative chemotherapy. 
 
Results: The median follow up was 73 months (9-231) for the 
entire cohort and 93 months (16-231) in survivors. 9 patients 
(22%) showed local failures, resulting in estimated 5-year and 
10-year local control rates of were 74% and 68%, 
respectively. 15 patients (37%) showed distant failures, 
transferring into estimated 5-year and 10-year distant control 
rates of 62% and 55%, respectively. Overall treatment failure 
was observed in 23 patients (56%), of whom 7 failed locally 
only, 15 distant only and 1 combined, resulting in 5- and 10-
year estimated FFTF rates of 44% and 32%, respectively.15 
patients have deceased, transferring into estimated 5-and 10-
year overall survival rates of 74% and 60%, respectively. 
Severe postoperative complications were observed in 14% of 
the patients, mainly as wound complications. Severe late 
toxicity was found in 19% of the patients. Preserved limb 
function without impairment in activities of daily living was 
achieved in 81% of the patients. 
 
Conclusion: Combination of surgery, IOERT and EBRT 
resulted in good local control and overall survival in recurrent 
soft tissue sarcomas of the extremities, although the results 
are worse than reported for primary situation. Given the high 
